Suppr超能文献

从正常人肝脏微粒体部分纯化及鉴定α1-蛋白酶抑制剂

Purification and characterization of alpha 1-proteinase inhibitor from microsomal fraction of normal human liver.

作者信息

Gan J C

出版信息

Biochim Biophys Acta. 1980 Dec 16;626(2):466-76. doi: 10.1016/0005-2795(80)90143-9.

Abstract

A plasma alpha 1-proteinase inhibitor was purified, for the first time, from the microsomal fraction of normal human liver by combined procedures of deoxycholate extraction, (NH4)2-SO4 precipitation, gel filtration and immunoadsorbent column chromatographies. The final yield of the material was approx. 15 mg/300 g liver. The preparation was shown to be homogeneous according to polyacrylamide gel electrophoretic and immunological criteria. The estimated molecular weight of the glycoprotein as determined by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis was 53 000, a value comparable to that reported for plasma alpha 1-proteinase inhibitor. The liver material was, however, devoid of trypsin-, chymotrypsin- or elastase-inhibitory activity. The loss of activity could be due to deoxycholate treatment during the extraction procedure. SDS-polyacrylamide gel electrophoresis of reduced (beta-mercaptoethanol) and alkylated (iodoacetamide) preparation revealed no change in mobility suggesting the presence of only polypeptide chain. The amino acid and carbohydrate compositions of the microsomal material were in close agreement with values reported in the literatures for the corresponding glycoprotein purified from the plasma. The liver microsomal alpha 1-proteinase inhibitor has a single amino terminal residue, namely, glutamic acid, as determined by the dansyl procedure, and a single carboxyl terminal residue, lysine as shown by the carboxypeptidase digestion method. These terminal amino acids are the same as those found in alpha 1-proteinase inhibitor purified from normal human plasma.

摘要

首次通过脱氧胆酸盐提取、硫酸铵沉淀、凝胶过滤和免疫吸附柱色谱等联合方法,从正常人肝脏的微粒体部分纯化出一种血浆α1-蛋白酶抑制剂。该物质的最终产量约为15毫克/300克肝脏。根据聚丙烯酰胺凝胶电泳和免疫学标准,该制剂显示为均一的。通过十二烷基硫酸钠(SDS)-聚丙烯酰胺凝胶电泳测定的糖蛋白估计分子量为53000,这一数值与报道的血浆α1-蛋白酶抑制剂的分子量相当。然而,肝脏来源的该物质缺乏胰蛋白酶、糜蛋白酶或弹性蛋白酶抑制活性。活性丧失可能是由于提取过程中的脱氧胆酸盐处理。还原(β-巯基乙醇)和烷基化(碘乙酰胺)制剂的SDS-聚丙烯酰胺凝胶电泳显示迁移率没有变化,表明仅存在多肽链。微粒体物质的氨基酸和碳水化合物组成与文献中报道的从血浆中纯化的相应糖蛋白的值密切一致。通过丹磺酰法测定,肝脏微粒体α1-蛋白酶抑制剂有一个单一的氨基末端残基,即谷氨酸,通过羧肽酶消化法显示有一个单一的羧基末端残基,赖氨酸。这些末端氨基酸与从正常人血浆中纯化的α1-蛋白酶抑制剂中的相同。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验